Results 21 to 30 of about 18,962 (231)

Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.

PLoS ONE, 2014
The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD).
Takeshi Osonoi, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida, Daisuke Tsujino, Rimei Nishimura, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis

Journal of Diabetes Research, 2020
Periodontitis is one of the diabetic complications due to its high morbidity and severity in patients with diabetes. The prevention of periodontitis is especially important in diabetic patients because the relationship between diabetes and periodontitis ...
Noritaka Sawada, Kei Adachi, Nobuhisa Nakamura, Megumi Miyabe, Mizuho Ito, Shuichiro Kobayashi, Shin-ichi Miyajima, Yuki Suzuki, Takeshi Kikuchi, Makoto Mizutani, Taku Toriumi, Masaki Honda, Akio Mitani, Tatsuaki Matsubara, Keiko Naruse   +14 more
doaj   +1 more source

Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux

Journal of Pharmacological Sciences, 2021
The incidence of diabetes–associated cognitive dysfunction is increasing. However, few clinical interventions are available to prevent the disorder.
Meng Zhang, Wenhui Yan, Ye Yu, Jie Cheng, Xinyao Yi, Tingli Guo, Na Liu, Jia Shang, Zhuanzhuan Wang, Hao Hu, Lina Chen   +10 more
doaj   +1 more source

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

Scientific Reports, 2017
Hepatic stellate cells (HSC) play a key role in the development of chronic liver disease (CLD). Liraglutide, well-established in type 2 diabetes, showed anti-inflammatory and anti-oxidant properties.
Fernanda Cristina de Mesquita, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Raquel Maeso-Díaz, Sergi Vila, Diana Hide, Martí Ortega-Ribera, José Luís Rosa, Juan Carlos García-Pagán, Jaime Bosch, Jarbas Rodrigues de Oliveira, Jordi Gracia-Sancho   +11 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Liraglutide Ameliorates β-Amyloid Deposits and Secondary Damage in the Ipsilateral Thalamus and Sensory Deficits After Focal Cerebral Infarction in Rats

Frontiers in Neuroscience, 2018
Focal cerebral infarction causes β-amyloid (Aβ) deposition and secondary neuronal degeneration in the ipsilateral thalamus. Thalamus is the subcortical center of sensory, the damage of thalamus could cause sensory deficits.
Hui-Li Zhu, Hui-Li Zhu, Zhang-Pei Liu, Zhang-Pei Liu, Wan-Yong Yang, Wan-Yong Yang, Da-Wei Dong, Da-Wei Dong, Ying Zhao, Ying Zhao, Bing Yang, Bing Yang, Li-An Huang, Li-An Huang, Yu-Sheng Zhang, Yu-Sheng Zhang, An-Ding Xu, An-Ding Xu   +17 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition

Discover Oncology
Background Liraglutide, a glucagon-like peptide-1 receptor agonist commonly used in diabetes management, has shown potential anti-cancer effects across various malignancies.
Xinjian Li, Minghu Fan, Rong Huang, Keqiang Wang, Hunan Huang   +4 more
doaj   +1 more source

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

PLoS ONE, 2018
BackgroundWe assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden.MethodsThe Swedish Institute for Health
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar   +4 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source